Q1 EPS Forecast for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research decreased their Q1 2027 earnings estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $1.83 for the quarter, down from their prior forecast of $1.86. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

Several other research analysts have also commented on HALO. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Finally, Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.89.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $60.03 on Wednesday. The firm has a market capitalization of $7.42 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 0.42 and a beta of 1.32. The stock has a fifty day moving average of $60.73 and a 200 day moving average of $55.32. Halozyme Therapeutics has a 52 week low of $38.88 and a 52 week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently added to or reduced their stakes in HALO. Virtu Financial LLC bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $434,000. World Investment Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth $3,293,000. Tidal Investments LLC raised its holdings in Halozyme Therapeutics by 265.5% in the 3rd quarter. Tidal Investments LLC now owns 20,576 shares of the biopharmaceutical company’s stock worth $1,178,000 after purchasing an additional 14,947 shares during the period. Castellan Group lifted its position in Halozyme Therapeutics by 4.5% during the third quarter. Castellan Group now owns 113,798 shares of the biopharmaceutical company’s stock valued at $6,514,000 after purchasing an additional 4,876 shares in the last quarter. Finally, Retirement Systems of Alabama grew its holdings in Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after purchasing an additional 74,173 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,697 shares of company stock valued at $1,558,052 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.